Core Viewpoint - JD Health (06618.HK) has reached a new high of 52.600 HKD, reflecting a 2.65% increase from the previous trading day, indicating strong market performance and investor interest [1] Company Overview - JD Health is the largest online healthcare platform in China and a leader in the digital transformation of the healthcare industry [1] - The company aims to create a comprehensive health management platform driven by digital technology, focusing on pharmaceutical and health product supply and medical services [1] Business Operations - JD Health's retail pharmacy and online healthcare services cater to various health needs, providing accessible, convenient, high-quality, and affordable medical products and services to the public [1] Financial Performance - As of August 6, JD Health experienced a net inflow of 47.5655 million HKD in capital, indicating positive investor sentiment [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 京东健康股份有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06618 | | 說明 | | | | | | | | | 多櫃檯證券代號 | 86618 | RMB | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 100,000,000,000 | USD | | 0.0000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | | 0 | | | | USD | | 0 | | 本月底結存 ...

Core Viewpoint - JD Health has evolved from a pharmaceutical e-commerce platform to a comprehensive healthcare service provider, focusing on self-operated pharmaceutical sales and expanding into various health services and solutions [1] Group 1: Business Overview - JD Health's self-operated business is the main driver of its performance, with a revenue of 48.8 billion in 2024, representing a year-on-year growth of 6.9%, accounting for 84% of total revenue [1] - The platform and digital marketing segment generated 9.4 billion in revenue in 2024, with a year-on-year growth of 19%, making up 16% of total revenue [1] - The company has over 100,000 third-party merchants on its platform and has integrated with more than 3,000 domestic medical insurance designated pharmacies for O2O services [1] Group 2: Market Trends - The online retail penetration of non-pharmaceutical products like nutritional supplements and home medical devices is expected to increase steadily over the next 2-3 years, with higher profit margins for these categories [1] - The online retail penetration rate for pharmaceuticals is currently low at approximately 13%, but user acceptance of online purchasing is growing, driven by trends in prescription drug distribution and increasing online insurance coverage [1] Group 3: Competitive Landscape - Competition in the internet healthcare sector has intensified since 2021, but is expected to stabilize by 2025, with JD Health leveraging its supply chain, service ecosystem, and AI technology to maintain a competitive edge [2] - The company has developed a closed-loop ecosystem for medical testing, diagnosis, and medication, enhancing its service offerings [2] Group 4: Financial Projections - Revenue projections for JD Health are estimated at 63.65 billion, 69.65 billion, and 76.55 billion for the years 2025 to 2027, with net profits of 4.52 billion, 5.04 billion, and 5.79 billion respectively [2] - The company is assigned a target market value of 180.7 billion based on a 40x price-to-earnings ratio for 2025, reflecting optimistic growth prospects [2]

Core Insights - The article highlights that JD Health has been recognized for its leading AI capabilities and applications in the healthcare sector, being included in the "2025 Sustainable Innovation Case Recommendation List" at the World Artificial Intelligence Conference [1][3]. Group 1: Recognition and Achievements - JD Health was selected for its significant contributions to sustainable innovation in the healthcare industry, alongside over 30 other renowned companies [3]. - The company has developed a series of AI medical products, including the "JD Medical Inquiry" model, which is the first fully open-source vertical model in China's medical industry [3][4]. Group 2: AI Model Development - The "JD Medical Inquiry" model is continuously upgraded, focusing on a "three engines + four models" architecture to enhance its capabilities in complex disease areas [4][10]. - The upgraded version "JD Medical Inquiry 2.0" integrates multi-source clinical information to provide reliable decision support for doctors, particularly in specialized disease treatment [8][9]. Group 3: Application and Impact - JD Health's AI applications have rapidly expanded across various healthcare scenarios, serving over 30 million users within six months of launching the "Kangkang" health assistant [11]. - The AI-driven services have lowered the barriers for users to access online medical consultations, allowing them to receive scientific advice without needing to visit a doctor first [12][13]. Group 4: Future Directions - JD Health aims to further enhance its AI capabilities by developing deep reasoning and multi-modal models to provide personalized and precise medical consultations [10]. - The company plans to expand its AI doctor program, aiming to cover more specialized areas and enhance the integration of online and offline healthcare services [11][13].

Group 1 - The core viewpoint of the report is that Credit Lyonnais has raised the adjusted net profit forecasts for JD Health (06618) by 5% and 6% for 2025 and 2026 respectively, reflecting better cost control [1] - The target price for JD Health has been increased from HKD 45 to HKD 56, indicating a positive outlook for the company [1] - JD Health is identified as a major beneficiary of JD Group's investment strategy focused on increasing app user growth [1] Group 2 - JD Health's performance in the first half of 2025 is reported to be strong, with total revenue growing by 23% year-on-year, reaching RMB 34.8 billion [1] - The revenue growth is attributed to the successful 618 shopping festival, particularly in the sales of nutritional health products and medical devices [1] - The outflow of original research drugs from hospital channels continues to support the demand for pharmaceuticals [1] Group 3 - The adjusted EBITDA is expected to increase by 57% year-on-year, reaching RMB 2.5 billion, driven by improved gross margins and strict control over investments in immediate demand [1]

Core Viewpoint - Credit Suisse has raised the adjusted net profit forecasts for JD Health (06618) for 2025 and 2026 by 5% and 6% respectively, reflecting better cost control, and increased the target price from HKD 45 to HKD 56 [1] Group 1: Financial Performance - JD Health's total revenue for the first half of 2025 is expected to grow by 23% year-on-year, reaching RMB 34.8 billion, driven by strong performance during the 618 shopping festival, particularly in the sales of nutritional health products and medical devices [1] - The adjusted EBITDA is projected to increase by 57% year-on-year, reaching RMB 2.5 billion, supported by improved gross margins and strict control over investments in immediate demand [1] Group 2: Market Position and Strategy - JD Health is identified as a major beneficiary of JD Group's aggressive investment strategy in app user growth [1] - The continued outflow of original research drugs from hospital channels is further supporting the demand for pharmaceuticals [1]

Core Viewpoint - Credit Suisse expects JD Health to show strong performance in the first half of 2025, with total revenue projected to grow by 23% year-on-year to reach 34.8 billion yuan, driven by the successful 618 shopping festival, particularly in the nutrition and medical device categories [1] Financial Performance - Total revenue for JD Health is expected to reach 34.8 billion yuan in the first half of 2025, reflecting a year-on-year growth of 23%, with a 20% increase in Q2 and a 26% increase in Q1 [1] - Adjusted EBITDA is projected to grow by 57% year-on-year to 2.5 billion yuan, supported by improved gross margins and strict control over investments in real-time demand [1] Profit Forecasts - Credit Suisse has raised its adjusted net profit forecasts for JD Health by 5% and 6% for 2025 and 2026, respectively, due to better cost control [1] - The target price for JD Health has been increased from 45 HKD to 56 HKD [1] Market Position - JD Health is identified as a major beneficiary of JD's aggressive investment strategy in app user growth [1] - The company maintains an "outperform" rating according to Credit Suisse [1]

Investment Rating - The report initiates coverage with a "Buy" rating for the company, considering its supply chain advantages, self-operated brand strengths, and the ability to continuously attract third-party merchants and expand O2O services, which are expected to drive steady growth in performance [6][7]. Core Insights - The company has transitioned from a pharmaceutical e-commerce platform to a comprehensive healthcare service provider, offering health product sales, medical services, and smart healthcare solutions, thereby achieving an online closed loop of medical services [14][17]. - The company's self-operated business is the core driver of its performance, with a significant revenue contribution from pharmaceutical and health product sales, which accounted for 84% of total revenue in 2024, growing by 6.9% year-on-year [6][17]. - The online healthcare market is expected to see accelerated penetration, particularly in non-pharmaceutical categories like nutritional supplements and home medical devices, while the pharmaceutical market's online penetration is anticipated to increase due to changing consumer behaviors and regulatory support [6][39]. Financial Data and Profit Forecast - The company forecasts revenues of 63.65 billion, 69.65 billion, and 76.55 billion CNY for 2025, 2026, and 2027 respectively, with net profits of 4.52 billion, 5.04 billion, and 5.79 billion CNY for the same years [6][7]. - The projected earnings per share (EPS) are expected to be 1.41, 1.58, and 1.81 CNY for 2025, 2026, and 2027 respectively, with a net asset return rate gradually increasing to 8.21% by 2027 [6][7]. Market Dynamics - The competitive landscape in the online healthcare sector is expected to stabilize by 2025, with the company leveraging its supply chain, service ecosystem, and AI capabilities to create competitive barriers [6][44]. - The report highlights that the online healthcare service market is still in its early stages, with significant growth potential driven by increased health awareness and the demand for personalized healthcare solutions [41][44]. Key Assumptions - The company anticipates continued growth in pharmaceutical and health product sales through deep collaboration with brand partners, supported by its supply chain advantages [8]. - The platform and advertising services are expected to grow rapidly, with revenue projections of 10.92 billion, 12.38 billion, and 14.04 billion CNY for 2025, 2026, and 2027 respectively [8].

Core Viewpoint - Eli Lilly's MuFenda® (Tirzepatide injection multi-dose pen) has been launched online on JD Health, marking a significant advancement in the treatment of type 2 diabetes and long-term weight management, leveraging its unique dual-action mechanism and efficacy [1][2]. Group 1: Product Launch and Features - MuFenda® is the first and only GIP/GLP-1 receptor agonist approved for type 2 diabetes and long-term weight management globally [1]. - The new multi-dose pen design incorporates an innovative "4-dose integration," allowing patients to use one dose per week, fulfilling a month's treatment needs [1]. - The pen can be stored at room temperature (not exceeding 30°C) for 30 days after the first use, enhancing convenience for patients [1]. Group 2: Patient Experience and Accessibility - The multi-dose pen is designed for ease of use, with simple steps for loading the needle, expelling air, adjusting the dose, and injecting, which improves patient comfort [2]. - JD Health expressed enthusiasm for collaborating with Eli Lilly to introduce MuFenda® multi-dose pen, aiming to enhance the purchasing experience for patients [2]. - The launch on JD Health is expected to benefit more patients with type 2 diabetes and obesity, promoting healthier lifestyles [2].

本报讯(记者袁传玺) 日前，礼来制药旗下穆峰达(替尔泊肽注射液多剂量预装笔)在京东健康股份有限公司(以下简称"京东健 康")线上首发。穆峰达作为全球首个且目前唯一获批用于2型糖尿病和长期体重管理的GIP/GLP-1受体激 动剂，自上市以来便以其独特的双重作用机制和显著的疗效，赢得了广大患者的信赖与好评。此次替尔 泊肽注射液多剂量预装笔，是礼来制药推出的新型注射装置，将为患者带来全新的选择。 京东健康相关负责人表示："我们非常高兴能够与礼来制药合作，率先引入穆峰达多剂量预装笔。这款 改进剂型将在京东买药秒送独家首发，并同步在京东买药上线，给患者带来更加方便、快捷的购买体 验。未来，我们将继续与全球药企紧密合作，共同推动新特药的普及和可及性，为更多患者提供精准、 高效的治疗方案。" 随着穆峰达多剂量预装笔在京东健康平台的线上首发，相信将有更多2型糖尿病和肥胖患者从中受益， 实现更加健康、美好的生活。 此次，礼来制药改进了穆峰达的注射装置。穆峰达(替尔泊肽注射液多剂量预装笔)采用了创新的"4剂集 成"设计，每支笔包含四个固定剂量，每周使用一个剂量，即可满足患者一个月的治疗需求。这一设计 不仅简化了用药流程，减少了患 ...